Induction of Cytosolic Phospholipase A2α Is Required for Adipose Neutrophil Infiltration and Hepatic Insulin Resistance Early in the Course of High-Fat Feeding
In established obesity, inflammation and macrophage recruitment likely contribute to the development of insulin resistance. In the current study, we set out to explore whether adipose tissue infiltration by neutrophils that occurs early (3 days) after initiating a high-fat diet (HFD) could contribute to the early occurrence of hepatic insulin resistance and to determine the role of cytosolic phospholipase A2α (cPLA2α) in this process. The 3-day HFD caused a significant upregulation of cPLA2α in periepididymal fat and in the liver. A specific antisense oligonucleotide (AS) effectively prevented cPLA2α induction, neutrophil infiltration into adipose tissue (likely involving MIP-2), and protected against 3-day HFD–induced impairment in hepatic insulin signaling and glucose over-production from pyruvate. To sort out the role of adipose neutrophil infiltration independent of cPLA2α induction in the liver, mice were injected intraperitoneally with anti–intracellular adhesion molecule-1 (ICAM-1) antibodies. This effectively prevented neutrophil infiltration without affecting cPLA2α or MIP-2, but like AS, prevented impairment in hepatic insulin signaling, the enhanced pyruvate-to-glucose flux, and the impaired insulin-mediated suppression of hepatic glucose production (assessed by clamp), which were induced by the 3-day HFD. Adipose tissue secretion of tumor necrosis factor-α (TNF-α) was increased by the 3-day HFD, but not if mice were treated with AS or ICAM-1 antibodies. Moreover, systemic TNF-α neutralization prevented 3-day HFD–induced hepatic insulin resistance, suggesting its mediatory role. We propose that an acute, cPLA2α-dependent, neutrophil-dominated inflammatory response of adipose tissue contributes to hepatic insulin resistance and glucose overproduction in the early adaptation to high-fat feeding.
Established obesity, particularly if associated with insulin resistance–related morbidities, is characterized by systemic and adipose tissue inflammation (1–3). The complexity of the adipocytokines and inflammatory cell types involved in adipose inflammation is constantly increasing, and today, most myeloid cell types have been implicated in the process, including macrophages, B cells, various T-cell classes, and even eosinophils and mast cells (4–6). In contrast, much less is known about adipose tissue and liver adaptation to a short-term high-fat diet (HFD) before overt obesity is present. Metabolically, it appears that hepatic insulin resistance may be a front-line response to a short-term (3 days) HFD (7,8), representing “physiological adaptation” and/or an early maladaptive response on the causal pathway to obesity-induced whole-body insulin resistance. It currently remains unclear to what degree this early response to an HFD involves immune cells in general and, specifically, in adipose tissue.
In a previous study, we demonstrated that during the first week of initiating an HFD, adipose tissue is infiltrated by neutrophils (9). Adipose tissue protein levels of the neutrophil-specific myeloperoxidase (MPO) were increased, and correspondingly, histology detected an increased number of neutrophils within the parenchyma of adipose tissue (i.e., not restricted to blood vessels). This early appearance of neutrophils in adipose tissue was recently confirmed (10), suggesting that adipose tissue inflammation in obesity largely follows the classical inflammation paradigms of acute versus chronic inflammatory cell infiltrates, predominated first by neutrophils, then lymphocytes in the subacute period, and finally, by mononuclear macrophages when inflammation becomes chronic. Yet, the co-occurrence of increased adipose neutrophil infiltration (9,10) with the early hepatic insulin resistance (7,8) prompts the question of whether the former phenomenon is causative for the latter.
Cytosolic phospholipase A2α (cPLA2α) has received much attention as a key regulator of inflammation. It plays a major role in the stimulus-initiated production of eicosanoids (prostaglandins and the chemoattractant leukotrienes) and platelet activating factor (11). In a previous study, we demonstrated that cPLA2α is upregulated in vascular endothelial cells in adipose tissue of mice in response to the 3-day HFD and that it mediates the elevated expression of the endothelial intracellular adhesion molecule (ICAM-1) (12) that is used for adhesion by neutrophils and monocytes. In addition, cPLA2α has been demonstrated to regulate superoxide generation by NADPH oxidase activation (13), thus promoting phagocyte-induced oxidative stress. Intriguingly, in humans, even a single exposure to a high-fat meal induced NADPH activation and inflammatory cascades in circulating leukocytes (14–16). These findings suggest that cPLA2α could participate in priming/activation of circulating cells upstream in inflammatory cascades that ultimately lead to adipose tissue infiltration by neutrophils, way before obesity has developed. In the current study, we set out to reveal the role of cPLA2α and adipose tissue neutrophil infiltration in the acute adaptation to a 3-day HFD, with emphasis on whether these early inflammatory responses could underlie the development of hepatic insulin resistance.
RESEARCH DESIGN AND METHODS
Animals and diets.
The study was approved by Ben-Gurion University Institutional Animal Care and Use Committee (IL-35–2006) and conducted according to the Israeli Animal Welfare Act, following the guidelines of the Guide for Care and Use of Laboratory Animals (National Research Council, 1996). Male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) at 6 weeks of age were fed a low-fat diet (LFD; 6% calories from fat; Harlan Teklad 2018sc) or an HFD (60% calories from fat; Research Diets #12492), as previously performed (17).
Mice were killed by CO2 at the indicated times, and periepididymal fat was dissected out and immediately fixed in 4% formaldehyde or snap-frozen and stored in liquid nitrogen until further analyzed. A combination of two oligonucleotides antisenses (AS) (TCAAAGGTCTCATTCCACA, GCTGTCAGGGGTTGTAG) and their corresponding senses, with phosphorothioate modifications on the last three bases at both 5′ and 3′ ends, was used as described previously (18).
For insulin stimulation, insulin was administered intravenously 5 min before the mice were killed, and livers or epididymal fat pads were immediately obtained and flash-frozen until analysis. Insulin doses of 0.5 and 2 units/kg gave identical signaling responses. LEAF-purified anti-mouse Ly-6G antibodies, LEAF-purified anti-mouse tumor necrosis factor (TNF)-α antibodies (MP6-XT22), and LEAF-purified anti-mouse CD54 antibodies and their isotype control IgG antibodies (BioLegend, San Diego, CA) were used for neutrophil depletion, TNF-α neutralization, and ICAM-1 neutralization, respectively.
Epididymal fat pads were lysed in ice-cold lysis buffer exactly as done earlier (9). Samples underwent 7.5% SDS-PAGE (for each 100-μg sample). The resolved proteins were electrophoretically transferred onto a nitrocellulose membrane, blocked in 5% milk in TBS-T (TBS containing 0.1% Tween-20), and incubated overnight at 4°C with goat anti-mouse MPO (1:100; Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-mouse β-actin (1:10,000), anti–phosphorylated (p)-Ser473 Akt (1:1000), anti-Akt (1:1000), anti–p-Ser9 glycogen synthase kinase (GSK; 1:1000), anti-GSK (1:1000), anti-cPLA2α (1:200; Cell Signaling, Beverly, MA), anti 5-lipoxygenase (5-LOX; 1:1000; Cayman Chemical, Ann Arbor, MI), or anti–cyclogenase-2 (COX-2; 1:1000; Abcam, Cambridge, U.K.). After being washed with TBS-T (four washes for 15 min each), the membranes were incubated with 1:10,000 dilutions of the respective horseradish peroxidase (HRP)–conjugated secondary antibodies for 1.5 h at room temperature. Proteins were quantified using video densitometry analysis (ImageGauge version 4.0, Fuji), as described previously (19,20).
Preparation of neutrophils.
Heart blood was withdrawn before mice were killed. Neutrophils, at 95% purity, were obtained by Ficoll-Hypaque centrifugation, dextran sedimentation, and hypotonic lysis of erythrocytes. Cells were counted, and their viability was determined by trypan blue exclusion.
Immunohistochemistry for neutrophil detection.
Epididymal fat tissues were embedded in paraffin and sectioned using a Leica microtome (Leica Biosystem, Vienna, Austria). Neutrophil staining by rat anti-mouse monoclonal anti–NIMP-R14 antibody to identify neutrophils (Novus Biological Inc.) was analyzed as done before (9,13), based on an earlier study (21). Nonspecific reactivity was blocked by incubating the slides with 20% normal rabbit serum for 20 min with avidin-biotin VECTA-STAIN Kit Elite PK 6105 (Vector Laboratories, Burlingame, CA). Sections were then incubated in 1:10 dilution of anti–NIMP-R14 antibodies in PBS for 1 h at room temperature, washed, and further incubated with 1:200 dilution of biotinylated anti-rat IgG, followed by avidin-biotin complex/HRP-DAB, which resulted in brown staining of neutrophils. For each treatment, a negative control was prepared without the primary antibody. The sections were counterstained with hematoxylin and analyzed in a blinded fashion using an Olympus BX-60 microscope.
The production of the superoxide anion by intact neutrophils was measured as the superoxide dismutase inhibitable reduction of acetyl ferricytochrome c by the microtiter plate technique, as previously described (22).
Cytokines and eicosanoids release measurements.
Epididymal fat tissue from mice was removed, weighed, sliced, and incubated for 3 h in 1 mL medium containing 0.1% BSA. The collected media were measured using commercial ELISA kits for TNF-α (Biolegend, San Diego, CA), 15 μg tissue for each sample, MIP-2, KC, leukotriene B4 (LTB4), IL-6 (all from R&D Systems, Inc., Minneapolis, MN), 150 μg tissue for each sample. Prostaglandin E2 (PGE2) levels were determined according to a dextran-coated charcoal radioimmunoassay protocol, using PGE2 standard, anti-PGE2 anti-serum (Sigma Israel, Rehovot, Israel), and [3H]PGE2 (Amersham Biosciences Corp., Piscataway, NJ), exactly as previously described (23).
Pyruvate tolerance test.
Pyruvate tolerance test was performed by intraperitoneal injection of pyruvate (2 g/kg body weight) in saline after an overnight fast. Blood glucose concentrations were measured in tail blood before and after injection at the times indicated (24). All glucose measurements were made using a glucometer (Abbott, Alameda, CA).
Homeostasis model assessment of insulin resistance.
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated by multiplying fasting plasma insulin concentration (mU/L) with fasting plasma glucose (mmol/L) divided by 22.5 (25–27). Plasma insulin levels were determined by ELISA (ALPCO Diagnostics, Salem, NH).
Glucose clamp studies.
Glucose clamp studies in freely moving mice were performed as described (28). Steady-state glucose infusion rate was calculated once glucose infusion reached a near-constant rate to maintain glucose at 5 mmol/L for 20 min. The glucose disposal rate was calculated by dividing the rate of [3-3H]glucose infusion by the plasma [3-3H]glucose-specific activity (29,30). Endogenous glucose production during the clamp was calculated by subtracting the glucose infusion rate from the glucose disposal rate (29,30). Insulin-stimulated glucose disposal rate was calculated by subtracting basal endogenous glucose production (equal to basal glucose disposal rate) from the glucose disposal rate during the clamp (31).
Data are presented as the mean ± SEM. Statistical significance for comparison between two groups was determined using the Student paired two-tailed t test, and by ANOVA for more than two treatment groups, followed by Bonferroni correction or by Newman-Keuls post hoc test, using GraphPad Prism 5.03 software.
The time-course of development of insulin resistance in response to the HFD was determined in liver and in periepididymal fat pads by assessing insulin-stimulated phosphorylation of Akt. At different times after initiating the HFD, mice received an intravenous insulin injection 5 min before livers were harvested. Three days after initiating the HFD, hepatic insulin-stimulated Ser473-Akt phosphorylation was markedly attenuated (Fig. 1A). At this time point of marked diminution of insulin signaling in the liver, adipose tissue exhibited normal insulin-stimulated Ser473-Akt phosphorylation (Fig. 1B). Insulin resistance in this tissue required a longer duration of HFD to manifest (data not shown). Nevertheless, the 3-day HFD was already sufficient to induce a statistically significant increase in adipose tissue weight (Fig. 1C) and a notable increase in adipocyte cell size (Fig. 1D). As reported in a previous study (9), multiple neutrophils were visible between adipocytes, indicating infiltration of the tissue parenchyma. (Fig. 1D). Concomitantly, histologic analysis showed hepatic lipid content was notably mildly increased in mice fed the 3-day HFD (Fig. 1E), as were fasting glucose levels (Table 1). Calculated HOMA-IR values revealed systemic insulin resistance induced by the 3-day HFD (Table 1).
We hypothesized that adipose tissue neutrophil infiltration induced by the 3-day HFD (9) could participate in the early induction of hepatic insulin resistance. To test this hypothesis, adipose neutrophil recruitment was first prevented using oligo-AS against cPLA2α. This approach was based on previous findings demonstrating 1) the effectiveness of AS administration in inhibiting neutrophil recruitment to the site of inflammation (13) and 2) that the 3-day HFD induces cPLA2α upregulation in adipose tissue (12). Mice received an intravenous tail vein injection of 1 mg/kg AS, 1 mg/kg corresponding (control) sense oligonucleotide, or saline 1 day before and then daily during the 3-day HFD. Weight gain was not affected by the AS or sense treatments (Fig. 2A), but AS treatment significantly prevented the elevated cPLA2α protein expression detected in lysates of adipose tissue of the 3-day HFD mice (Fig. 2B). The AS treatment also significantly prevented the recruitment of neutrophils to the adipose tissue of the HFD mice, as detected by adipose protein levels of MPO (Fig. 2C) and by quantitation of neutrophils by NIMP-R14 immunostaining (Fig. 2D).
To analyze whether AS protected against hepatic insulin resistance, insulin induction of liver p-Ser473–Akt or p-Ser9–GSK-3β was assessed (32,33). AS, but not sense treatment, prevented HFD-induced impairment of insulin-stimulated Akt and GSK-3β phosphorylation (Fig. 2E and F), without affecting liver histology (data not shown). AS treatment did not affect the normal insulin signaling in the adipose tissue (data not shown). At the whole-body metabolic level, the 3-day HFD was associated with an exaggerated glucose production during a pyruvate tolerance test compared with LFD mice, and this enhanced pyruvate-to-glucose flux was prevented by AS compared with the sense-treated mice (Fig. 2G).
Liver cPLA2α was also upregulated by the 3-day HFD, and as in adipose tissue, this increased expression was prevented by AS treatment (Fig. 3A). However, neutrophil infiltration to adipose tissue seemed to constitute a unique response of this tissue to the 3-day HFD, because no similar elevation occurred in the levels of the neutrophil-selective protein MPO in the liver (Fig. 3B). Thus, AS directed against cPLA2α decreased the elevated expression of this phospholipase in adipose tissue and in the liver and concomitantly prevented the tissue-selective neutrophil infiltration into adipose tissue that was induced by the 3-day HFD. These effects were associated with prevention of impaired hepatic insulin signaling and enhanced pyruvate-to-glucose flux that developed during early adaptation to the HFD.
To further support the role of neutrophil recruitment to adipose tissue in inducing liver insulin resistance and to differentiate its effect from the possible consequences of increased expression of cPLA2α in the liver, anti–ICAM-1 antibodies were used to prevent neutrophil recruitment. Mice were injected intraperitoneally with 100 μg anti-mouse ICAM-1 antibodies or isotype control IgG antibodies every other day, beginning 2 days before the HFD was initiated. Treatment with anti–ICAM-1 antibodies, but not with control IgG antibodies, reduced MPO expression in adipose tissue (Fig. 4A) and the number of neutrophils, as analyzed histologically by NIMP-R14, from 11.56 ± 1.2 to 3.49 ± 0.9 neutrophils per high-power field (P < 0.001), indicating the prevention of adipose neutrophil recruitment, without affecting body weight (Fig. 4B). Importantly, this approach to prevent HFD-induced adipose neutrophil infiltration did not attenuate the diet-induced elevation in cPLA2α protein expression in the liver (Fig. 4C). Inhibition of neutrophil infiltration to adipose tissue significantly improved hepatic insulin signaling, as detected by insulin-stimulated p-Akt and p-GSK (Fig. 4D and E), without affecting liver histology (data not shown) or adipose insulin signaling (not shown) and, consistently, alleviated the augmented gluconeogenic flux from pyruvate induced by the 3-day HFD (Fig. 4F).
To further confirm that prevention of adipose infiltration by neutrophils improved hepatic insulin sensitivity, hyperinsulinemic-euglycemic clamp studies were conducted. The glucose infusion rate was significantly decreased in HFD-fed mice (Fig. 4G and Supplementary Fig. 1). However, no difference was observed between IgG- and ICAM-treated mice (Fig. 4G and Supplementary Fig. 1). Insulin-mediated inhibition of endogenous (mainly reflecting hepatic) glucose production was significantly reduced in IgG-treated HFD-fed mice (Fig. 4H). In contrast, ICAM-treated HFD-fed mice showed a conserved response to insulin, suggesting improved hepatic insulin sensitivity in ICAM-treated compared with IgG-treated HFD-fed mice (Fig. 4H). Of note, the 3-day HFD did not significantly affect the insulin-stimulated glucose disposal rate (mainly reflecting skeletal muscle insulin sensitivity), although a slight decrease was apparent in the group treated with anti–ICAM-1 (Fig. 4I). High variability in the insulin-stimulated glucose disposal rate may have prevented a significant difference in the glucose infusion rate between the two HFD-fed groups (Fig. 4G). These hyperinsulinemic-euglycemic clamp results are consistent with a state of selective hepatic insulin resistance induced by the 3-day HFD, which can be alleviated by anti–ICAM-1 antibodies that prevent adipose tissue neutrophil infiltration.
To gain further support for the role of adipose neutrophil infiltration in the induction of hepatic insulin resistance, neutrophil infiltration was prevented by an alternative approach (i.e., by neutrophil depletion using Ly6G-specific monoclonal antibody), as described (34,35). Mice were injected intraperitoneally with 150 μg anti-mouse Ly-6G antibodies or isotype control IgG antibodies 1 day before the 3-day HFD was initiated. Neutrophil depletion was validated by fluorescence-activated cell sorter analysis using rat anti-mouse neutrophils antibodies (MCA771F, Serotec), as performed in a previous study (13). Neutrophil depletion significantly improved hepatic insulin responsiveness, as detected by insulin-stimulated p-Akt (Fig. 4J) and p-GSK (Fig. 4K). Collectively, inhibiting adipose neutrophil infiltration, independent of attenuating cPLA2α induction early after initiating the HFD, prevented the early diet-induced hepatic insulin resistance and glucose overproduction.
We next assessed possible mechanisms related to 1) neutrophil adaptation to HFD and recruitment to adipose tissue and 2) the induction of hepatic insulin resistance in this specific model of short-term hypernutrition. Neutrophil tissue infiltration is a process associated with cellular activation and with specific chemoattractants that direct these cells to the site of inflammation. Indeed, peripheral blood neutrophils from mice fed the 3-day HFD released significantly higher levels of superoxides (Fig. 5A), suggesting that neutrophil activation is induced by the diet. Consistent with our previous report (13), the AS treatment attenuated the release of superoxides.
Several putative adipose tissue–derived neutrophil chemoattractants are known as potent activators. These factors include the cPLA2-dependent metabolite LTB4, previously shown by us to recruit neutrophils to the peritoneal cavity of a mouse model of sterile peritonitis (13), and the neutrophil-selective chemoattractant IL-8. The IL-8 ortholog in mice is keratinocyte chemoattractant (KC or CXCL1), and MIP-2 (CXCL2), both ligands for the chemokine receptor CXCR2 (36). Epididymal fat tissue from 3-day HFD–fed mice and control (3-day LFD) mice expressed similar levels of 5-LOX protein and released similar levels of LTB4, with no effect on these parameters by AS treatment (Fig. 5B and C). Similarly, secretion of the neutrophil chemoattractant KC was not affect by 3-day HFD or by the AS treatment (Fig. 5D). Yet, a significantly increased secretion of MIP-2 from adipose tissue of the 3-day HFD mice was detected (Fig. 5E and F). AS-treated 3-day HFD mice secreted significantly lower levels of MIP-2, similar to those of the control mice (Fig. 5E), suggesting that cPLA2α is involved in regulation of MIP-2 production. In contrast, treatment of the 3-day HFD mice with anti–ICAM-1 antibodies did not attenuate MIP-2 secretion (Fig. 5F), suggesting that cPLA2α upregulation, but not the consequential neutrophil infiltration, is involved in adipose tissue MIP-2 production. Jointly, these findings suggest a putative role for adipose MIP-2 as a chemoattractant involved in neutrophil recruitment to the epididymal fat tissue early after initiating the HFD.
To shed light on the mechanisms by which neutrophil infiltration to adipose tissue might induce hepatic insulin resistance, we determined if secretion/expression of PGE2, COX2, and the proinflammatory cytokines IL-6 and TNF-α are increased already 3 days after initiating the HFD. cPLA2α and COX2 are both robustly increased in various tissues during active inflammatory processes, and PGE2, the metabolite of arachidonic acid, has been recently implicated in insulin resistance (37). Yet, no increase in COX2 expression or PGE2 secretion from adipose tissue was observed in 3-day HFD mice (Fig. 6A) compared with control mice (Fig. 6B). There was also no increase in the secretion of IL-6 (Fig. 6C), but TNF-α (Fig. 6D and E) was significantly elevated in adipose tissue of the HFD-fed mice, an effect of the diet, prevented by AS or anti–ICAM-1 antibodies. To further establish the mediatory role of TNF-α in hepatic insulin resistance after the 3-day HFD, TNF-α was neutralized, using anti-mouse IgG1 monoclonal antibody, as in a previous study (38). Mice were injected intraperitoneally with 150 μg anti-mouse TNF-α antibodies or isotype control IgG1 antibodies 1 day before initiation of the HFD and at day 2 of the HFD. The elevated serum TNF-α levels in HFD mice (8.7 ± 0.9 compared with 5.5 ± 0.7 pg/mL in LFD mice) was significantly (P < 0.001) reduced by anti–TNF-α antibodies treatment (4.5 ± 0.6 pg/mL) but not by control IgG1 antibodies (8.1 ± 0.7 pg/mL). Serum TNF-α neutralization significantly improved hepatic insulin responsiveness, as detected by insulin-stimulated p-Akt and p-GSK (Fig. 6F and G).
The current study shows that hepatic insulin resistance induced by a short-term HFD reflects a dysregulated adipose-to-liver axis that is initiated by a cPLA2α-mediated, neutrophil-predominated, adipose tissue inflammation. Our studies reveal that:
2) Recruitment of neutrophils to adipose tissue is critical for the induction of hepatic insulin resistance in response to the 3-day HFD. Increased adipose tissue TNF-α secretion may constitute a mediator in this response, because increased TNFα secretion and hepatic insulin resistance were both prevented when neutrophil infiltration was attenuated, and neutralizing TNF-α significantly prevented hepatic insulin resistance.
3) The recruitment of neutrophils to adipose tissue likely involves cPLA2α-dependent MIP-2 secretion.
Consistent with our previous (9) and present studies, recruitment of neutrophils to adipose tissue after 3 days of the HFD was recently confirmed by others (10), and the role of adipose tissue neutrophils in insulin resistance was also demonstrated. Adipose tissue recruitment of neutrophils is also consistent with a study demonstrating increased leukocyte–endothelial cells–platelet interaction in the microcirculation of visceral adipose tissue in obesity (39). Moreover, in humans, pregnant obese women with preeclampsia exhibited extensive vascular inflammation characterized predominantly by neutrophils, demonstrable in adipose tissue blood vessels (40). The current study, however, offers several novel observations and mechanistic insights: the 3-day HFD constitutes a unique state predominantly affecting hepatic insulin responsiveness, independent of skeletal muscle, and/or adipose tissue insulin resistance that apparently takes longer to develop. Under such conditions of “isolated hepatic insulin resistance,” we were able to demonstrate that neutrophil recruitment, specifically to adipose tissue (and not to the liver), is necessary for hepatic insulin resistance to develop. Moreover, induction of adipose cPLA2α upregulation is deemed necessary for adipose tissue neutrophil infiltration and is upstream of an inflammatory pathway involving the upregulation of the neutrophil chemoattractant MIP-2, the upregulation of the endothelial adhesion molecule ICAM-1 (12), and the adipose tissue neutrophil–dependent increased production of TNF-α. Importantly, although cPLA2α is upregulated also in the liver, as was neutrophil elastase in a recent study,(10) our results assign a role specifically for adipose, and not hepatic, cPLA2α upregulation in the induction of hepatic insulin resistance and glucose overproduction: By antagonizing ICAM-1, 3-day HFD–induced increase in cPLA2α was still present, but adipose tissue neutrophil infiltration was prevented, and hepatic insulin resistance was still averted. We thus provide compelling evidence that adipose cPLA2α-mediated neutrophil infiltration, specifically to adipose tissue, contributes to hepatic insulin resistance in response to acute short-term high-fat feeding. It may be speculated that this early inflammatory response to a HFD, consistent with studies in human circulating leukocytes (14–16), represents, at least in the short-term, a physiological adaptation: isolated hepatic insulin resistance with preserved adipose tissue insulin sensitivity would assist in directing more storage of excess calories in adipose tissue and less in ectopic sites.
Recruitment of different immune cell types to adipose tissue and consequential changes in secretion of cytokines have been documented in recent years, mainly at much later time points of diet-induced obesity. These include CD11c+, M1-like macrophages (2,4,41,42), and B and CD8+ T cells (43–45). However, the recruitment of lymphocytes to adipose tissue was not directly linked with induction of insulin resistance (5). Although Kupffer cells were proposed to mediate the induction of hepatic insulin resistance by 3-day HFD (7), another study reported opposite results (8), suggesting that whereas macrophage-mediated tissue inflammation is a key component of chronic obesity-associated insulin resistance, it is not critical for the decrease in insulin sensitivity at the early adaptation to HFD feeding. We therefore propose that most likely, in the acute response to HFD, neutrophils may well constitute the major driver of adipose tissue inflammation and hepatic insulin resistance.
cPLA2α was recently suggested to be involved in the storage of lipids in the adipose tissue and liver during prolonged obesity (46) and in 3T3-L1 cells (47). In the current study, prevention of cPLA2α upregulation by AS treatment in the 3-day HFD mice did not interfere with weight gain. Thus, cPLA2α regulates the adaptation to the 3-day HFD independent of weight gain or adipocyte hypertrophy. The results of the current study suggest that MIP-2, a mouse ortholog of human IL-8, signals neutrophils recruitment downstream of cPLA2α (Fig. 6). This observation may also be highly relevant for humans in whom adipose tissue IL-8 levels were elevated (48–50). MIP-2 has been shown to be one of the major inducible chemokines with the ability to attract neutrophils to the site of inflammation (51). KC and MIP-2 have temporally distinct patterns of expression and cell type-specificity (52). MIP-2 was shown to be produced by resident macrophages and by neutrophils (36,51). Therefore, in response to the 3-day HFD, MIP-2 is likely produced by resident macrophages and not by neutrophils, because MIP-2 production was reduced only with the AS treatment and not with anti–ICAM-1 antibodies treatment, whereas in both treatments, the recruitment of neutrophils to the adipose fat was prevented. Because MIP-2 synthesis is Toll-like receptor (TLR)–dependent (36) and saturated free fatty acids act as a naturally occurring ligands of macrophage TLR4 (53), it is possible that elevation of free fatty acid in the intra-abdominal adipose tissue by the 3-day HFD triggers the production of cPLA2α-dependent MIP-2 in resident macrophages, leading to neutrophil recruitment. Thus, cPLA2α facilitates neutrophil recruitment by two important steps of the process: the secretion of the chemoattractant MIP-2 and the production of the adhesion molecule ICAM-1 (12).
We show here that circulating neutrophils are activated in mice fed the 3-day HFD, as shown by the release of superoxides (Fig. 5A). This is consistent with the immediate activation of circulating neutrophils, the release of superoxides, increased expression of NADPH oxidase, and the increased proinflammatory cytokines demonstrated in healthy human subjects exposed to a high-fat meal or a high-fat-carbohydrate meal or during a glucose challenge (14–16,54–57). The activated adipose neutrophil-produced factors that mediate hepatic insulin resistance have yet to be identified. Although neutrophil elastase is a likely candidate (10), it should be remembered that this was demonstrated at 12 weeks of the HFD, when its expression was also elevated in the liver. LTB4 or PGE2 were shown to impair insulin signaling (37,58), and adipose tissue LTB4 secretion was recently reported to contribute to elevation of adipose macrophages and T cells at 15 weeks of an HFD (59). Yet, they are unlikely to be involved in the response to the 3-day HFD. Elevated local and circulating levels of TNF-α and IL-6 are known to be associated with obesity in humans and rodent models (60–62), and both cytokines have been shown to induce hepatic insulin resistance (63,64). Although there was no increase in adipose secretion of IL-6 at the 3-day HFD, here we show that adipose tissue released significantly higher levels of TNF-α and that prevention of neutrophil infiltration to adipose tissue significantly attenuated this response. TNF-α blood levels were significantly elevated by the short-term HFD, consistent with a recent study (8), and neutralizing these elevated TNF-α levels prevented the development of hepatic insulin resistance by the 3-day HFD, further supporting its causal role in the process. In accordance with our results, a much higher increase in TNF-α than in IL-6 gene expression in adipose tissue at day 3 of the HFD was reported (8). We thus propose TNF-α as a potential mediator of primed adipose tissue neutrophils in causing hepatic insulin resistance induced by the 3-day HFD.
In conclusion, we show here that adipose cPLA2α has a profound role in initiating hepatic insulin resistance during the early response to hypernutrition. Adipose cPLA2α has a major role in promoting infiltration of activated neutrophils to adipose tissue in a short-term HFD, probably by increasing the production of the neutrophil chemoattractant MIP-2 and upregulating ICAM-1. The presence of neutrophils in the adipose tissue induces elevated secretion of TNF-α, which likely contributes to the early development of isolated hepatic insulin resistance.
N.H. was supported by a grant from Goldman Faculty Fund for Medical Research in Community Health of the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. A part of the work was supported by research grants from the Swiss National Science Foundation (No. 310030-141238, to D.K.).
No potential conflicts of interest relevant to this article were reported.
N.H. researched the data and reviewed the manuscript. O.B., V.E.-C., and Y.S. researched the data. S.W., F.I., and D.K. conducted and interpreted the clamp studies. A.R. contributed to study conceptualization, results interpretation, and participated in writing and reviewing the manuscript. R.L. designed the study and wrote the manuscript. R.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1300/-/DC1.
- Received September 21, 2012.
- Accepted May 5, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.